+351 211 369 829 INFO@OPHIOMICS.COM

Ophiomics wins the SME Instrument Phase I

Ophiomics was granted the SME Instrument Phase I grant to conduct a Feasibility study for its HepatoPredict genomic signature for Liver Cancer. Check here for the CORDIS page. This grant will permit Ophiomics to build a business case for HepatoPredict.

Share the Post:

Back to news list

Related Posts

Ophiomics @ EASL Milan 2024

Ophiomics is present @EASL2024 in Milan. Visit us at Biotech Village BT3 to discover how HepatoPredict will

@ Voice Leadership Program

We are very happy to have been selected to participate in the Voice Leadership Program in the Training and Mentorship

Ophiomics @ ILTS Houston

Just back from three days of intense learning and networking with leaders in liver transplantation from all over the world.

Ophiomics at the Esophagus Conference

Discussing the challenges of early and accurate diagnosis of displasia and how biomarkers can be the key to saving more